Alexion Pharmaceuticals AAQS 2024

Mitä Alexion Pharmaceuticals tekee?

Alexion Pharmaceuticals Inc. is a US biotechnology company specializing in the development and commercialization of drugs for the treatment of rare diseases. It was founded in 1992 and is headquartered in Boston, Massachusetts. The history of Alexion began with the discovery of the protein C5a, which is responsible for the occurrence of inflammation. Alexion then developed the first medication, Soliris, specifically for the treatment of the rare genetic disease paroxysmal nocturnal hemoglobinuria (PNH). Soliris is classified as a monoclonal antibody and inhibits the protein C5a, which is responsible for inflammation. Alexion's business model focuses primarily on developing drugs for rare diseases. These diseases are unprofitable for most major pharmaceutical companies because they have a small patient base. However, Alexion has begun to identify and develop drugs for such diseases that are tailored to these specific patients. Such drugs are not suitable for the majority of the patient population as they are very expensive. Alexion is divided into several divisions focused on the development and launch of drugs for specific diseases. The most well-known division is PNH, but the company has also developed drugs for rare hematological, nephrological, neurological, immunological, and metabolic diseases. Alexion has also developed the ability to bring drugs to market faster than other pharmaceutical companies by employing innovative clinical trial methods. In addition to Soliris, Alexion has developed other drugs such as Ultomiris, Strensiq, and Kanuma. Ultomiris is a successor to Soliris and is used to treat PNH and aHUS. Strensiq is used for patients with hypophosphatasia, while Kanuma was developed for patients with lysosomal storage diseases such as children with Gaucher disease or Fabry disease. Alexion also collaborates with other companies to develop and market drugs for rare diseases. The most well-known example is the collaboration with the Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation to develop the drug ALXN1210, which Alexion hopes will surpass both Soliris and Ultomiris. The collaboration has the potential to provide groundbreaking treatment for PNH, aHUS, and other rare diseases. Overall, in recent years, Alexion Pharmaceuticals Inc. has become an important player in the market for rare diseases. The company has taken on challenging tasks by striving to uncover rare diseases and gaps and then finding new, unique solutions to treat these diseases. In the future, Alexion will continue its efforts in researching and developing drugs for rare diseases and will continue to provide innovative solutions and therapeutic approaches to improve the lives of patients. Alexion Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.